Sanofi (EURONEXT:SAN) reported Phase 3 Baby-COMET success for Nexviazyme in infantile-onset Pompe—meeting primary and secondary endpoints, well tolerated with no serious treatment-related AEs—and said a U.S. label filing is expected in H2 2026 while Q2 results arrive July 30, 2026.
Previous Week Recap
- Nexviazyme Meets Endpoints, Pompe Baby-COMET: Sanofi (SAN): Nexviazyme met primary and secondary endpoints in Phase 3 Baby-COMET for infantile-onset Pompe, was well tolerated, no serious treatment-related AEs; U.S. label filing expected H2 2026.
- Sanofi Q2 2026 Results Date: Sanofi SA (SAN) posted a Q2 2026 aide-mémoire on its Investors page for financial modeling and confirmed Q2 2026 results will be released July 30, 2026.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.